Cite
MLA Citation
James C-H Yang et al.. “Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.” Lancet oncology, vol. 16, no. 7, n.d., pp. 830–838. http://access.bl.uk/ark:/81055/vdc_100025942553.0x000015